Psychiatrists for Depression in Washington, DC

· Updated November 2026 · McLean Neuropsychiatric Treatment Center

Depression

Specialty care for depression, just across the Potomac

If you live or work in Washington, DC and depression has not improved enough with standard treatment, a specialty evaluation is a reasonable next step. McLean Neuropsychiatric Treatment Center (McLean NTC) is a psychiatrist-led interventional psychiatry and neuromodulation center in McLean, Virginia, just across the Potomac River from the District. We focus on treatment-resistant depression, obsessive-compulsive disorder and complex mood disorders.

Who you will see

Every plan starts with a psychiatric evaluation with one of our clinicians: psychiatrists, psychiatric nurse practitioners and a physician assistant, each board-certified in their field. The team is led by our founder and medical director, Aazaz Haq, MD, a board-certified adult and geriatric psychiatrist who specializes in treatment-resistant depression, complex mood disorders and interventional psychiatry. Meet our clinicians.

What the first visit answers

The first consultation answers one question: what is the most appropriate next step? Your clinician reviews symptoms, diagnosis, prior treatment, medications, therapy history, medical conditions, safety and goals. The result may be a recommendation for TMS, esketamine, ketamine, medication management, OCD TMS, VNS evaluation, ECT referral, psychotherapy referral, or a higher level of care.

Many people labeled treatment-resistant were never on the right dose for long enough, or have a condition that was missed. A careful review of what has been tried comes first.

Treatments available at our clinic

We do not perform ECT at our clinic. When ECT is the most appropriate option, we refer you to a program that provides it.

What published studies show

In a naturalistic study of 307 patients treated with TMS in clinical practice, 58% responded and 37% reached remission (Carpenter et al., Depression and Anxiety, 2012). In the TRANSFORM-2 trial, 69% of patients responded to esketamine plus a new antidepressant at four weeks, compared with 52% on an antidepressant plus placebo (Popova et al., American Journal of Psychiatry, 2019). These figures come from published studies, not from our clinic, and individual results vary.

Coming from Washington, DC

We are at 6849 Old Dominion Drive, Suite 315, McLean, VA 22101, with early morning, evening and weekend appointments. Treatments are given in person at the clinic. After a TMS session you can drive yourself. After esketamine or ketamine you cannot drive until the next day, so plan a ride home before each visit.

Insurance

We accept many major plans, including Medicare, Virginia Medicaid and Tricare. Coverage varies by plan; our insurance team checks your benefits for you. Ketamine is self-pay.

For psychiatrists and therapists in Washington, DC

We are a consultation and treatment partner for psychiatrists, therapists, primary care clinicians and hospitals. We evaluate, treat, send our recommendations back and return patients to your ongoing care. Referral information.

How to start

Call (571) 378-1398 or request a consultation. Our patient advocate calls you back within one business day. Your first visit is an evaluation, not a commitment to any treatment.

Key takeaways

  • McLean NTC is a psychiatrist-led clinic in McLean, Virginia that serves patients from Washington, DC.
  • The first visit is an evaluation that reviews your diagnosis and what has already been tried.
  • TMS, esketamine, ketamine, TMS for OCD, VNS evaluation and medication management are available at one clinic.
  • We accept many major plans, including Medicare, Virginia Medicaid and Tricare.

Sources

Carpenter LL, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety, 2012.

Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression (TRANSFORM-2). American Journal of Psychiatry, 2019.

Ready to take the next step?

Your first consultation is an evaluation, not a commitment to any treatment. Our patient advocate calls you back within one business day.

Or call us(571) 378-13986849 Old Dominion Drive, Suite 315, McLean
Call (571) 378-1398Request a consultation